Activation of RANKL/RANK/OPG system has been implicated in rheumatoid arthritis (RA), Crohn’s disease (CD) and ulcerative colitis (UC) [16, 50]; moreover RANKL blockade improves hepatic insulin resistance and prevents development of diabetes [51]. Here, TNFRSF11A is linked to diabetes mellitus.